Zila Nutraceuticals has developed and patented a new form of
Ester-C said to offer improved antioxidant and anti-carcinogenic
potential, which should allow it to maintain its advantage in the
vitamin C market until the end of next...
Zila Nutraceuticals are continuing their expansion into south east
Asia with a new agreement with Lohaspia to distribute its Ester-C
advanced vitamin C ingredient in Taiwan and Korea.
Zila Nutraceuticals felt the pinch of lower Ester-C sales in the US
in Q1 2006, when net revenues fell by 15 percent. But the company
expects strong sales on the international front to restore it to
its growth trajectory before the...
Zila Nutraceuticals, the US firm that makes enhanced absorption
vitamin C and E, is expanding its sales in Europe with two separate
agreements in the Scandinavian region.
DSM is to close down production of bulk vitamin C in the US and cut
costs at its plant in Dalry, Scotland, as part of a series of
measures to ease pressure on its vitamin business, reports
Dominique Patton.
Low vitamin C prices are boosting margins at Phoenix firm Zila,
which generates three quarters of its turnover from enhanced forms
of vitamin C and E, reports Dominique Patton.
Zila announced its results for the first quarter of fiscal 2005
this week, showing that its nutraceuticals division continues to
lead the company forward.
Nearly half of the US population suffers from acid problems meaning
they are unable to take acidic supplements such as vitamin C. One
company thinks it has found a radical solution to this problem in
the form of Comfort C.
Zila, a US pharma and biotech company, has achieved double-digit
sales growth for the first half of 2004, mainly due to the
performance of its nutraceutical division. Operational costs
exceeded sales however, due to higher cost of...
A surge in sales of its Ester-C brand in the nutraceuticals
division helped pharma and biotech company Zila offset an overall
loss for the first quarter, knocked by higher ascorbic acid costs.
The nutraceuticals unit of pharma company Zila saw a 75 per cent
increase in revenue in the third quarter, driven by sales of its
core vitamin C product Ester-C, the company reported.
Further evidence to suggest that vitamin C intake may reduce the
risk of some cancers and other chronic diseases was released this
week by US researchers.
